GRAFORCE
24.1.2023 19:01:49 CET | Business Wire | Press release
Graforce, Germany’s leading provider of zero carbon hydrogen plants, and Kawasaki Gas Turbine Europe GmbH (Kawasaki), a European gas turbine and heat-power cogeneration business, are cooperating for zero-emission heat and power generation. The joint innovative plant concept combines Graforce's methane electrolysis technology (plasmalysis) with hydrogen turbines from Kawasaki. First customer projects for this zero carbon heat and power solution are in the works.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230123005010/en/
Hydrogen turbines and methane electrolysis are game changers for an electricity-independent zero carbon heat-power cogeneration. (Photo: Business Wire)
“Our joint zero-emission plant is a breakthrough for the decarbonization of both, fossil fuels and manufacturing industries”, explains Dr. Jens Hanke, CTO of Graforce. “This technology generates CO2-free high-temperature heat via hydrogen, the carbon black is used as a raw material in production, and – best of all, the process is self-sufficient and does not need further electricity after having been started. This in turn relieves the strain on power grids.”
Decarbonization of industrial processes
The new plant solution generates hydrogen from biomethane, natural gas, LNG or LPG by methane electrolysis technology. The hydrocarbons will remain the initial source, but instead of being burnt, a high frequency plasma splits the hydrocarbons into CO2-free hydrogen and carbon black.
The hydrogen is converted to electricity in Kawasaki's hydrogen gas turbine and reused for hydrogen production in the plasma electrolyzer. The ultra-high temperature CO2-free exhaust gas from the hydrogen gas turbine can be used in production processes in various industries. Companies that previously generated high-temperature heat with natural gas can significantly increase their overall efficiency while reducing their gas and especially electricity costs.
Carbon black is used as a synthetic raw material for industrial production. This way, CO2 can be sequestered long-term in steel, cement or for soil enhancement. For industries which require both high temperatures and large quantities of carbon black for production this process pays off twice – in terms of climate protection and cost-effectiveness.
Beyond industry, this hydrogen-based heat-power cogeneration plant can be used for CO2-free heating in surrounding urban areas.
Both technologies were awarded with the Innovation Award of the German Gas Industry, in 2020 and 2022.
About
Kawasaki Gas Turbine Europe GmbH
The German company, 100% subsidiary of Kawasaki Heavy Industries, LTD. (Japan), providing natural gas and hydrogen gas turbine generator set to improve the energy efficiency for various industries and to contribute the global environmental conservation. http://www.kawasaki-gasturbine.de/en
Graforce GmbH
Graforce is German hydrogen technology company developing and manufacturing Power-to-X plants to decarbonize fossil energies, industrial sectors and the heat, transport and building sectors. The company is currently in a process to expand its strategic partnerships with financial as well as strategic investors to quickly scale its hydrogen technology worldwide. www.graforce.com/EN
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230123005010/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom